Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K N Moore

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2020
The forefront of ovarian cancer therapy: update on PARP inhibitorsM R Mirza, R L Coleman, A González-Martín, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 6, 2021
Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159]M R Mirza, R L Coleman, A González-Martín, et al.
Gynecologic Oncology Reports|February 4, 2021
PARPi after PARPi in epithelial ovarian cancerK G Essel, K Behbakht, T Lai, et al.
Gynecologic Oncology Reports|November 14, 2019
Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumabJ Gillen, K A Mills, J Dvorak, et al.
Gynecologic Oncology|May 2, 2013
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancerK M Moxley, D M Benbrook, L Queimado, et al.
Gynecologic Oncology|April 6, 2020
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaL R Duska, G R Petroni, N Varhegyi, et al.
Gynecologic Oncology|December 14, 2011
Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?E K Nugent, E A Bishop, C A Mathews, et al.
Gynecologic Oncology|May 17, 2011
Malignant melanoma of the vulva: an extension of cutaneous melanoma?K M Moxley, A N Fader, P G Rose, et al.
Gynecologic Oncology|December 7, 2024
Clinical trial screening in gynecologic oncology: Defining the need and identifying best practicesT Castellano, O D Lara, C McCormick, et al.
Contemporary Clinical Trials|February 23, 2025
Design of a randomized controlled trial to test the efficacy of interrupting sitting on type 2 diabetes risk factors in children with overweight/obesity: The sedentary behavior study 3 protocolB R Belcher, K L McAlister, J Zink, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2020
The forefront of ovarian cancer therapy: update on PARP inhibitorsM R Mirza, R L Coleman, A González-Martín, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 6, 2021
Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159]M R Mirza, R L Coleman, A González-Martín, et al.
Gynecologic Oncology Reports|February 4, 2021
PARPi after PARPi in epithelial ovarian cancerK G Essel, K Behbakht, T Lai, et al.
Gynecologic Oncology Reports|November 14, 2019
Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumabJ Gillen, K A Mills, J Dvorak, et al.
Gynecologic Oncology|May 2, 2013
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancerK M Moxley, D M Benbrook, L Queimado, et al.
Gynecologic Oncology|April 6, 2020
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaL R Duska, G R Petroni, N Varhegyi, et al.
Gynecologic Oncology|December 14, 2011
Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?E K Nugent, E A Bishop, C A Mathews, et al.
Gynecologic Oncology|May 17, 2011
Malignant melanoma of the vulva: an extension of cutaneous melanoma?K M Moxley, A N Fader, P G Rose, et al.
Gynecologic Oncology|December 7, 2024
Clinical trial screening in gynecologic oncology: Defining the need and identifying best practicesT Castellano, O D Lara, C McCormick, et al.
Contemporary Clinical Trials|February 23, 2025
Design of a randomized controlled trial to test the efficacy of interrupting sitting on type 2 diabetes risk factors in children with overweight/obesity: The sedentary behavior study 3 protocolB R Belcher, K L McAlister, J Zink, et al.
Pageof 7